Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02020941 · ClinicalTrials.gov registry record · Phase 2
Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy
A Phase 2 study, sponsored by Attaya Suvannasankha.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT02020941: Clinical Trial Phase 2 study, sponsored by Attaya Suvannasankha.
NCT02020941 is a Phase 2 study that was terminated before completion, run by Attaya Suvannasankha. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02020941, a Phase 2 study, was terminated before completion, sponsored by Attaya Suvannasankha.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER laboratory biomarker analysis
- DRUG dexamethasone
- DRUG carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02020941
The ClinicalTrials.gov registry entry for NCT02020941 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Attaya Suvannasankha, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT02020941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02020941 about?
NCT02020941 is a clinical study titled "Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy". This phase II trial studies how well carfilzomib works in treating patients with multiple myeloma in first relapse or refractory to first-line therapy. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT02020941?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2013-09. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02020941?
The interventions under investigation include: laboratory biomarker analysis (OTHER), dexamethasone (DRUG), carfilzomib (DRUG).
Who is sponsoring clinical trial NCT02020941?
This trial is sponsored by Attaya Suvannasankha, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.